The increasing complexity of cancer chemotherapy makes it mandatory that pharmacists be familiar with these highly toxic agents. This column focuses on the commercially available and investigational agents used to treat malignant diseases and reviews issues related to the preparation, dispensing, and administration of cancer chemotherapy.
Get full access to this article
View all access options for this article.
References
1.
National Comprehensive Cancer Network.NCCN multiple myeloma practice guidelines v.1.2004.The Complete Library of NCCN Oncology Practice Guidelines [CD-ROM]. Rockledge, PA: National Comprehensive Cancer Network; 2004.
FriedenbergW.R., KyleR.A., KnospeW.H.High-dose dexamethasone for refractory or relapsing multiple myeloma.Am J Hematol.1991; 36: 171–5.
4.
AlexanianR., DimopoulosM.A., DelasalleK.Primary dexamethasone treatment of multiple myeloma.Blood.1992; 80: 887–90.
5.
AlexanianR., HautA., KhanA.U.Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens.JAMA.1969; 208: 1680–5.
6.
BarlogieB., SmithL., AlexanianR.Effective treatment of advanced multiple myeloma refractory to alkylating agents.N Engl J Med.1984; 310: 1353–6.
7.
RajeN., AndersonK.Thalidomide: A revival story.N Engl J Med.1999; 341: 1606–9.
8.
SinghalS., MehtaJ., DesikanR.Antitumor activity of thalidomide in refractory multiple myeloma.N Engl J Med.1999; 341: 1565–71.
9.
PalumboA., GiacconeL., BertolaA.Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced multiple myeloma.Haematologica.2001; 86: 399–403.
10.
DimopoulosM.A., ZervasK., KouvatseasG.Thalidomide and dexamethasone combination for refractory multiple myeloma.Ann Oncol.2001; 12: 991–5.
11.
AlexanianR., WeberD., GiraltS.Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy.Ann Oncol.2002; 13: 1116–9.
12.
RajkumarS.V., HaymanS., GertzM.A.Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.J Clin Oncol.2002; 20: 4319–23.
13.
WeberD., RankinK., GavinoM.Thalidomide alone or with dexamethasone for previously untreated multiple myeloma.J Clin Oncol.2003; 21: 16–9.
14.
AnagnostopoulosA., WeberD., RankinK.Thalidomide and dexamethasone for resistant multiple myeloma.Br J Haematol.2003; 121: 768–71.
15.
ErikssonT., HoglundP., TuressonI.Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis.J Pharm Pharmacol.2003; 55: 1701–6.
